Gastric Perforation Presenting as Empyema in a Patient with Pancreatic Cancer on Bevacizumab Treatment

被引：0

作者：

Shao, Yu-Yun ^{[1
]}

Lin, Zhong-Zhe ^{[1
]}

Liang, Po-Chin ^{[2
]}

Tien, Yu-Wen ^{[3
]}

Cheng, Ann-Lii ^{[1
,4
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10002, Taiwan

[2] Natl Taiwan Univ Hosp, Dept Med Imaging, Taipei 10002, Taiwan

[3] Natl Taiwan Univ Hosp, Dept Surg, Taipei 10002, Taiwan

[4] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10002, Taiwan

来源：

ANTICANCER RESEARCH | 2009年 / 29卷 / 05期

关键词：

Bevacizumab; empyema; gastrointestinal perforation; pancreatic cancer; OVARIAN-CANCER; THERAPY; TRIAL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bowel perforation is a rare but life-threatening complication of bevacizumab, a new anticancer treatment. Patients with bowel perforation usually present with acute abdominal symptoms. Here a case history is presented to highlight a pancreatic cancer patient on bevacizumab chemotherapy who developed empyema as the first manifestation of gastric perforation. This unusual presentation warns physicians that bevacizumab-related bowel perforation can arise as a thoracic complication, without typical gastrointestinal manifestations, in an advanced cancer patient.

引用

页码：1665 / 1667

页数：3

共 7 条

[1] Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer
Cohn, David E.
Valmadre, Sue
Resnick, Kimberly E.
Eaton, Lynne A.
Copeland, Larry J.
Fowler, Jeffrey M.
[J]. GYNECOLOGIC ONCOLOGY, 2006, 102 (02) : 134 - 139
[2] Managing patients treated with bevacizumab combination therapy
Gordon, MS
Cunningham, D
[J]. ONCOLOGY, 2005, 69 : 25 - 33
[3] Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab
Gray, Jhanelle
Murren, John
Sharma, Anupama
Kelley, Scott
Detterbeck, Frank
Bepler, Gerold
[J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (06) : 571 - 573
[4] Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer
Kindler, HL
Friberg, G
Singh, DA
Locker, G
Nattam, S
Kozloff, M
Taber, DA
Karrison, T
Dachman, A
Stadler, WM
Vokes, EE
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 8033 - 8040
[5] Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
Miller, KD
Chap, LI
Holmes, FA
Cobleigh, MA
Marcom, PK
Fehrenbacher, L
Dickler, M
Overmoyer, BA
Reimann, JD
Sing, AP
Langmuir, V
Rugo, HS
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 792 - 799
[6] Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer
Monk, Bradley J.
Han, Ernest
Josephs-Cowan, Carol A.
Pugmire, Gordon
Burger, Robert A.
[J]. GYNECOLOGIC ONCOLOGY, 2006, 102 (02) : 140 - 144
[7] Gastropleural fistula originating from the lesser curve: a recognised complication, an uncommon pathway of communication
Virlos, I
Asimakopoulos, G
Forrester-Wood, C
[J]. THORACIC AND CARDIOVASCULAR SURGEON, 2001, 49 (05) : 308 - 309

← 1 →